PASSAGE BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
PASSAGE BIO, INC. (PASG) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 254.74 thousand shares for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-09-03
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 63.23K shares.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 191.51K shares, a 94.66% decline year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 1.13K shares, a 99.74% decline year-over-year.
- PASSAGE BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2019 was 998.87K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 63.23K shares derived: S-4/A 6 month − S-4 3 month · filed 2026-09-03 | 254.74K shares S-4/A · filed 2026-09-03 | 254.74K shares derived: sum of 3 quarters · filed 2026-09-03 | 255.87K shares derived: sum of 4 quarters · filed 2026-09-03 |
| 2026-03-31 | 191.51K shares S-4 · filed 2026-07-21 | 191.51K shares derived: sum of 2 quarters · filed 2026-09-03 | 192.63K shares derived: sum of 3 quarters · filed 2026-09-03 | -3.15M shares derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-12-31 | 0.00 shares derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | 1.13K shares derived: sum of 2 quarters · filed 2026-09-03 | -3.34M shares derived: sum of 3 quarters · filed 2026-09-03 | 248.21K shares S-4/A · filed 2026-09-03 |
| 2025-09-30 | 1.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -3.34M shares derived: sum of 2 quarters · filed 2025-11-10 | 248.21K shares 10-Q · filed 2025-11-10 | |
| 2025-06-30 | -3.34M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 247.08K shares 10-Q · filed 2025-08-12 | ||
| 2025-03-31 | 3.59M shares 10-Q · filed 2025-05-13 | |||
| 2024-09-30 | 429.74K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 1.15M shares derived: sum of 2 quarters · filed 2024-11-13 | 4.79M shares 10-Q · filed 2024-11-13 | |
| 2024-06-30 | 719.36K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 4.36M shares 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | 3.64M shares 10-Q · filed 2024-05-14 | |||
| 2023-09-30 | 150.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 398.07K shares derived: sum of 2 quarters · filed 2023-11-13 | 3.35M shares 10-Q · filed 2023-11-13 | |
| 2023-06-30 | 247.57K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 3.20M shares 10-Q · filed 2023-08-07 | ||
| 2023-03-31 | 2.95M shares 10-Q · filed 2023-05-11 | |||
| 2022-09-30 | 266.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 2.82M shares derived: sum of 2 quarters · filed 2022-11-10 | 5.71M shares 10-Q · filed 2022-11-10 | |
| 2022-06-30 | 2.55M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 5.44M shares 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | 2.89M shares 10-Q · filed 2022-05-16 | |||
| 2021-09-30 | 1.00M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 3.50M shares 10-Q · filed 2021-11-04 | ||
| 2021-06-30 | 2.50M shares 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | 998.87K shares 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |